Thrilled for the Parkinson’s Disease community, in particular the patients, who should be availed of blarcamesine immediately.
Controlled trial. Stat sig. Dose dependent IMPROVEMENTS from baseline. Serious unmet need. Improved sleep. Safe. No SAE’s. Oral administration. Improvements in PD motor skills/movements, and in PD dementia.
Now I understand why the Doctors that had ACTUALLY reviewed our data, Drs Jaime Kulisevsky Bojarski, MD, PhD and Dag Aarsland, MD, were “extremely encouraged” in their previous PDD blarcamesine 2-73 comments.
“Principal investigator Jaime Kulisevsky Bojarski, MD, PhD, professor of neurology, and vice-dean, faculty of medicine, Autonomous University of Barcelona, and director of the movement disorders unit, department of neurology, Sant Pau Hospital, said in a statement, "As the first double-blind trial of ANAVEX 2-73 (blarcamesine) in PDD, this proof-of-concept study provides extremely encouraging data. PDD can be debilitating with significant co-morbidities. New therapies are urgently needed to alleviate this suffering and disability.””
And
“”Given the limited options of adequate treatments for Parkinson’s disease dementia, and the safety concerns and modest or uncertain efficacy of currently used off-label treatments, the ANAVEX 2-73 (blarcamesine) study results represent a meaningful step forward toward urgently needed treatment for this serious complication of Parkinson’s disease,” Dag Aarsland, MD, PhD, professor, and head, department of old age psychiatry, Institute of Psychiatry, Psychology & Neurosciences, King’s College London, said in a statement.”
